Table 4.
Combined genotypes associated with urinary bladder cancer risk
| Genotypea | BC patients n (%) | Controls n (%) | P value | OR (95 % CI)b | P value |
|---|---|---|---|---|---|
| GSTM1xGSTA1 | 150 (61.7) | 265 (72.6) | 0.005 | Ref. | |
| GSTM1xGSTA1 variant | 93 (38.3) | 100 (27.4) | 1.56 (1.08–2.26) | 0.02 | |
| GSTP1xGSTT1 | 233 (96.3) | 320 (87.7) | 0.0001 | Ref. | |
| GSTP1xGSTT1 variant c | 9 (3.7) | 45 (12.3) | 0.24 (0.11–0.51) | <0.0001 | |
| GSTT1xSOD2 | 220 (90.9) | 311 (85.4) | 0.05 | Ref. | |
| GSTT1xSOD2 variant | 22 (9.1) | 53 (14.6) | 0.55 (0.32–0.96) | 0.04 | |
| GSTP1xGSTT1xSOD2 | 226 (97.5) | 334 (91.8) | 0.003 | Ref. | |
| GSTP1xGSTT1xSOD2 variant | 6 (2.5) | 30 (8.2) | 0.22 (0.09–0.56) | 0.001 |
aVariant genotypes grouping heterozygous with homozygous minor alleles and GSTM1 null, GSTT1 null genotypes; reference genotypes grouping the remaining combination of major, minor and null alleles; the number of subjects may vary from investigated individuals due to GSTT1 and GSTA1 genotyping failure
bAdjusted to age, sex and smoking habit
c P heterogeneity = 0.01